Our vision is to improve the treatment of severe diseases. Working with the medicines of the future we focus on oncology.

Human Health

Human HealthOur main goal is to develop new pharmaceuticals with high versatility were there are wide-spread medical needs.

Further reading »


Animal Health

Animal HealthAnimal Health develops and improves existing medical treatments focusing on oncology.

Further reading »


The Share

Latest News

Year-end report for the fiscal year May 2014 – April 2015

June 4 2015
Paclical har fått marknadsgodkännande i Ryssland
Further reading »

Changes in Oasmia’s Board of Directors and Management

May 29 2015
Uppsala, Sweden – May 29, 2015. At the extraordinary general meeting held on May 28, 2015 a resolution was made to elect Hans Liljeblad and Lars Bergkvist as new Members of the Board and that Julian Aleksov succeeds Joel Citron as Executive Chairman of the Board. The Board appointed Mikael Asp as new CEO for Oasmia.
Further reading »

Communiqué from Oasmia’s Extraordinary General Meeting 2015

May 29 2015
Oasmia Pharmaceutical AB (publ.), with VAT no SE556332-667601, held its Extraordinary General Meeting on Thursday, May 28, 2015, where the following main resolutions were made. For detailed information about the content of the resolutions, see the complete notice for the Extraordinary General Meeting which is available on Oasmia’s website www.oasmia.com, together with the complete proposals for the resolutions below.
Further reading »

bottom